AI Article Synopsis
- Liposomes are phospholipid vesicles that serve as drug and gene carriers, especially for cancer treatment.
- There are two targeting strategies for liposome delivery: passive targeting, which relies on their ability to accumulate in tumors through leaky blood vessels, and active targeting, which involves adding ligands to liposomes to bind specific cancer cell antigens.
- The review discusses the progress and challenges in developing antibody-targeted liposomes loaded with anticancer drugs for clinical use.
Article Abstract
Liposomes, phospholipid vesicles with a bilayered membrane structure, have been widely used as pharmaceutical carriers for drugs and genes, in particular for treatment of cancer. To enhance the efficacy of the liposomal drugs, drug-loaded liposomes are targeted to the tumors by means of passive (enhanced permeability and retention mediated) targeting, based on the longevity of liposomes in blood and its accumulation in pathological sites with compromised vasculature, and active targeting, based on the attachment of specific ligands to the liposomal surface to bind certain antigens on the target cells. Antibody-targeted liposomes loaded with anticancer drugs demonstrate high potential for clinical applications. This review highlights evolution of liposomes for both passive and active targeting and challenges in development of targeted liposomal therapeutics specifically antibody-targeted liposomes.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3326155 | PMC |
| http://dx.doi.org/10.1208/s12248-012-9330-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prevention of liver cancer in the era of next-generation antivirals and obesity epidemic.
Hepatology
January 2025
Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Preventive interventions are expected to substantially improve the prognosis of patients with primary liver cancer, predominantly hepatocellular carcinoma (HCC) and cholangiocarcinoma. HCC prevention is challenging in the face of the evolving etiological landscape, particularly the sharp increase in obesity-associated metabolic disorders, including metabolic dysfunction-associated steatotic liver disease (MASLD). Next-generation anti-HCV and HBV drugs have substantially reduced, but not eliminated, the risk of HCC and have given way to new challenges in identifying at-risk patients.
View Article and Find Full Text PDFPrecision Medicine for High-Risk Gene Fusions in Pediatric AML: a focus on KMT2A, NUP98, and GLIS2 Rearrangements.
Blood
January 2025
Children's Hospital of Philadelphia & University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States.
Robust genetic characterization of paediatric AML has demonstrated that fusion oncogenes are highly prevalent drivers of AML leukemogenesis in young children. Identification of fusion oncogenes associated with adverse outcomes has facilitated risk stratification of patients, although successful development of precision medicine approaches for most fusion-driven AML subtypes have been historically challenging. This knowledge gap has been in part due to difficulties in targeting structural alterations involving transcription factors and in identification of a therapeutic window for selective inhibition of the oncofusion without deleterious effects upon essential wild-type proteins.
View Article and Find Full Text PDFFactors Influencing Postoperative Quality of Life in Korean Brain Tumor Survivors.
J Neurosci Nurs
January 2025
Soomin Lim, MD RN, College of Nursing, Seoul National University, Seoul, Korea.
BACKGROUND: Patients with brain tumors continue to exhibit a lower quality of life than the general population, even after an extended period after surgery. Therefore, this study aimed to assess the postoperative quality of life of patients with brain tumors in South Korea and explore its determinants. METHODS: This study used a descriptive correlational design and collected data using questionnaires and electronic medical records.
View Article and Find Full Text PDFPolydopamine-Mediated, Centrifugal Force-Driven Gold Nanoparticle-Deposited Microneedle SERS Sensors for Food Safety Monitoring Theoretical Study of the SERS Substrate Fabrication.
ACS Sens
January 2025
The Education Ministry Key Lab of Resource Chemistry, Shanghai Key Laboratory of Rare Earth Functional Materials, Shanghai Municipal Education Committee Key Laboratory of Molecular Imaging Probes and Sensors, and Department of Chemistry, Shanghai Normal University, Shanghai 200234, P. R. China.
Microneedle (MN) sensors have great promise for food safety detection, but the rapid preparation of MNs for surface-enhanced Raman scattering (SERS) sensors with tunable and homogeneous nanoparticles remains a great challenge. To address this, a SERS sensor of gold nanoparticles@polydopamine@poly(methyl methacrylate) MN (AuNPs@PDA@PMMA-MN) was developed. The extended-Derjaguin-Landau-Verwey-Overbeek theory was applied to calculate the interaction energy between AuNPs and PDA.
View Article and Find Full Text PDFAccelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials.
J Clin Oncol
January 2025
The Kinghorn Cancer Centre, St Vincent's Hospital, Sydney, NSW, Australia.
Purpose: Over the past 15 years, the landscape of early phase clinical trials (EPCTs) has undergone a remarkable expansion in both quantity and intricacy. The proliferation of sites, trials, sponsors, and contract research organizations has surged exponentially, marking a significant shift in research conduct. However, EPCT operations suffer from numerous inefficiencies, such as cumbersome start-up processes, which are particularly critical when drug safety and the recommended phase II dose need to be established in a timely manner.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!